These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25904940)

  • 21. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I; Alavi A
    Int J Dermatol; 2002 Aug; 41(8):521-4. PubMed ID: 12207774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
    Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
    J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.
    Khamesipour A; Mohammadi A; Jaafari M; Eskandari S; Tasbihi M; Javadi A; Afshari F; Mortazavi H; Firooz A
    East Mediterr Health J; 2022 Sep; 28(9):658-663. PubMed ID: 36205204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the effect of oral clarithromycin on acute cutaneous leishmaniasis lesions compared with systemic glucantime.
    Zabolinejad N; Layegh P; Abbasi Shaye Z; Salehi M; Ghanizadeh S
    J Dermatolog Treat; 2022 May; 33(3):1418-1423. PubMed ID: 32972289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison Of Oral Dapsone With Intramuscular Meglumine Antimoniate In Cutaneous Leishmaniasis.
    Ahmed N; Malik S; Tahir M; Rahman A; Fayyaz I; Raza N; Iftikhar N
    J Ayub Med Coll Abbottabad; 2022; 34(4):802-806. PubMed ID: 36566403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by
    Eskandari SE; Khamesipour A; Jaafari MR; Javadi A; Mohammadi AM; Valian HK; Nassiri-Kashani M; Goyonlo VM; Firooz A
    Iran J Microbiol; 2021 Oct; 13(5):718-723. PubMed ID: 34900170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of oral itraconazole and intramuscular meglumine antimoniate in the treatment of cutaneous leishmaniasis.
    Saleem K; Rahman A
    J Coll Physicians Surg Pak; 2007 Dec; 17(12):713-6. PubMed ID: 18182133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis.
    Rahman A; Tahir M; Naveed T; Abdullah M; Qayyum N; Malik DH; Amin B
    J Coll Physicians Surg Pak; 2023 Dec; 33(12):1367-1371. PubMed ID: 38062590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis.
    López-Jaramillo P; Rincón MY; García RG; Silva SY; Smith E; Kampeerapappun P; García C; Smith DJ; López M; Vélez ID
    Am J Trop Med Hyg; 2010 Jul; 83(1):97-101. PubMed ID: 20595484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
    Sadeghian G; Nilfroushzadeh MA; Iraji F
    Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interventions for American cutaneous and mucocutaneous leishmaniasis.
    Pinart M; Rueda JR; Romero GA; Pinzón-Flórez CE; Osorio-Arango K; Silveira Maia-Elkhoury AN; Reveiz L; Elias VM; Tweed JA
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004834. PubMed ID: 32853410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
    Rajabi O; Layegh P; Hashemzadeh S; Khoddami M
    Dermatol Ther; 2016 Sep; 29(5):358-363. PubMed ID: 27073044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis.
    Bashir U; Tahir M; Anwar MI; Manzoor F
    Pak J Med Sci; 2019; 35(6):1669-1673. PubMed ID: 31777513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological Trend of Cutaneous Leishmaniasis in an Endemic Focus Disease During 2009-2016, Central Iran.
    Moein D; Masoud D; Mahmood N; Abbas D
    Turkiye Parazitol Derg; 2019 Jun; 43(2):55-59. PubMed ID: 31204455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC; Rabello A; Cota GF
    PLoS One; 2017; 12(9):e0184777. PubMed ID: 28926630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
    Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: A triple-blind randomized controlled clinical trial.
    Parvizi MM; Handjani F; Moein M; Hatam G; Nimrouzi M; Hassanzadeh J; Hamidizadeh N; Khorrami HR; Zarshenas MM
    PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005957. PubMed ID: 28981503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis.
    Layegh P; Rajabi O; Jafari MR; Emamgholi Tabar Malekshah P; Moghiman T; Ashraf H; Salari R
    J Parasitol Res; 2011; 2011():656523. PubMed ID: 22174993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I; Farajzadeh S; Rahnama Z; Fathabadi EA; Heshmatkhah A
    Int J Dermatol; 2012 Oct; 51(10):1221-5. PubMed ID: 22994669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.